When performing deep sedation in children undergoing magnetic resonance imaging (MRI) studies, anesthesiologists often are on the lookout for a drug that will not inhibit airway patency. A trial by a group of Buffalo researchers has concluded that dexmedetomidine may be one such alternative, as it causes no more airway collapses than propofol in these patients.
Fonte: Anesthesiology News
Leggi il resto di questo articolo »
Si chiama Touch Tb ed è un manuale multimediale sulla tubercolosi scaricabile gratuitamente da ibook Store. Il progetto è stato realizzato in collaborazione tra il dipartimento di Prevenzione della Asl di Milano e l’Università di Milano, è contiene anche immagini video e animazioni per un percorso interattivo di conoscenza della patologia. E’ dedicato a studenti e operatori.
Patients with atrial fibrillation (AF) receiving antithrombotic treatment are at increased risk for bleeding if they also take a nonsteroidal anti inflammatory drug (NSAID), even for a short period, a new nationwide Danish study has found.
The data suggest that a serious bleeding event occurs in up to 1 in 400 to 500 patients with AF exposed to an NSAID for 2 weeks and that the risk is elevated with both selective cyclooxygenase (COX)-2 inhibitors and nonselective NSAIDs.
CHICAGO — A new trial shows no benefit of low-dose, once-daily aspirin in the primary prevention of cardiovascular events in patients with multiple risk factors, including hypertension, diabetes, and dyslipidemia. No benefit was seen for the composite endpoint of nonfatal myocardial infarction (MI), nonfatal stroke, or death from cardiovascular causes. There were significant reductions in MI and in transient ischemic attack (TIA), but a significant increase in serious extracranial hemorrhage meant the net benefit was questionable. The overall rate of events was much lower than anticipated in this study, and it did not reach statistical significance, said study coauthor Kazuyuki Shimada, MD, Department of Cardiology, Shin-Oyama City Hospital, Tochigi, Japan. "Therefore, the possibility that aspirin does have a beneficial effect in this population cannot be excluded." Still, the clinical importance of aspirin for primary prevention was "less than originally anticipated in this population," he concluded, and further analyses are planned to see whether they can identify patients who may benefit most from aspirin. "Lastly, it will be interesting to see if the ongoing studies ARRIVE, ASCEND, ASPREE and ACCEPT-D, which are assessing primary prevention in predominantly Western populations, have different outcomes to our study in Japanese patients," Dr Shimada said. The results of the Japanese Primary Prevention Project (JPPP) were published online November 17 in JAMA to coincide with presentation here at the American Heart Association 2014 Scientific Sessions.
Il risarcimento del danno in favore dei medici specializzandi nel periodo 1983/1991 comporta esclusivamente gli interessi e non anche la rivalutazione salva la prova del maggior danno subito e dalla messa in mora in considerazione del fatto che, con la monetizzazione avutasi con la L. n. 370 del 1999, l’obbligazione risarcitoria acquistò il carattere di un’obbligazione di valuta.
In questi termini si è espressa la Suprema Corte che ha anche escluso il risarcimento del danno da perdita di chance che esige la prova, anche presuntiva, dell’esistenza di elementi oggettivi e certi dai quali desumere, in termini di certezza o di elevata probabilità e non di mera potenzialità, l’esistenza di un pregiudizio economicamente valutabile. Ai fini del riconoscimento, occorre allegare e provare della concreta intenzione, da parte dei medici specializzati in quegli anni di spendere il titolo in ambito europeo.
[Avv. Ennio Grassini – www.dirittosanitario.net]
Tags: sentenze